Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Nephrology
•
End stage kidney disease
How would you approach managing a patient with ESKD on peritoneal dialysis who has a milky appearance of peritoneal effluent but low peritoneal fluid triglyceride levels?
Related Questions
Do you have a preference between midodrine and droxidopa for patients with ESKD who experience intradialytic hypotension?
What are your top takeaways from ASN Kidney Week 2025?
What is your approach to using intraperitoneal sodium thiosulfate for a patient with ESKD on peritoneal dialysis who develops calciphylaxis?
Would you consider treating hypercalcemia with CRRT and regional citrate anticoagulation for a dialysis dependent patient who does not respond to bisphosphonate therapy and low calcium dialysate bath?
Would you consider not returning the blood from the dialysis circuit as a strategy for managing polycythemia in a patient with ESKD on hemodialysis who has a hemoglobin level greater than 16 g/dL?
Is there a role for vadadustat in addition to an ESA in ESKD patients who are hyporesponsive to ESA’s alone?
Would you avoid fistula placement in patients with ESKD secondary to scleroderma?
Would you make any dialysis prescription modifications for an ESKD patient who develops tachycardia during a hemodialysis session?
How would you approach the timing of hemodialysis for an ESKD patient with no urgent indications who has NSTEMI with a troponin level of 10 ng/dl, has not had dialysis in 2 days, and is planned for left heart catheterization the next day?
What is your approach to managing ESKD patients who are disruptive and threatening in the dialysis unit?
